Cipla to launch generic Cinacalcet hydrochloride tablets

06 Mar 2019 Evaluate

Cipla and its subsidiary Cipla USA, Inc., will launch a phase of generic Cinacalcet hydrochloride tablets (30mg, 60mg and 90mg) in the USA. The launch is a subject of ongoing litigation. The company's cinacalcet hydrochloride tablets (30mg, 60mg and 90mg) is AB-rated generic therapeutic equivalent version of Sensipar, a branded drug marketed by Amgen, Inc.

Cinacalcet tablets are indicated for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on dialysis, for the treatment of hypercalcemia in adult patients with Parathyroid Carcinoma, and for treatment of severe hypercalcemia in adult patients with primary HPT who are unable to undergo parathyroidectomy.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. The company’s portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.

Cipla Share Price

1433.75 -13.85 (-0.96%)
14-Jan-2026 15:17 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1700.10
Dr. Reddys Lab 1185.20
Cipla 1433.75
Zydus Lifesciences 884.25
Lupin 2195.15
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×